It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Improved understanding of the molecular mechanisms responsible for the progression from a “non-pathogenic” steatotic state to Non-Alcoholic Steatohepatitis is an important clinical requirement. The cell death-inducing DFF45 like effector (CIDE) family members (A, B and FSP27) regulate hepatic lipid homeostasis by controlling lipid droplet growth and/or VLDL production. However, CIDE proteins, particularly FSP27, have a dual role in that they also regulate cell death. We here report that the hepatic expression of CIDEA and FSP27 (α/β) was similarly upregulated in a dietary mouse model of obesity-mediated hepatic steatosis. In contrast, CIDEA expression decreased, but FSP27-β expression strongly increased in a dietary mouse model of steatohepatitis. The inverse expression pattern of CIDEA and FSP27β was amplified with the increasing severity of the liver inflammation and injury. In obese patients, the hepatic CIDEC2 (human homologue of mouse FSP27β) expression strongly correlated with the NAFLD activity score and liver injury. The hepatic expression of CIDEA tended to increase with obesity, but decreased with NAFLD severity. In hepatic cell lines, the downregulation of FSP27β resulted in the fractionation of lipid droplets, whereas its overexpression decreased the expression of the anti-apoptotic BCL2 marker. This, in turn, sensitized cells to apoptosis in response to TNF α and saturated fatty acid. Considered together, our animal, human and in vitro studies indicate that differential expression of FSP27β/CIDEC2 and CIDEA is related to NAFLD progression and liver injury.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Université Côte d’Azur, INSERM, U1065, C3M, Nice, France; Université Côte d’Azur, CHU, INSERM, U1065, C3M, Nice, France
2 Université Côte d’Azur, INSERM, U1065, C3M, Nice, France
3 AP-HP - Université Paris Est Créteil, HU Henri Mondor, Department of Pathology, Créteil, France (GRID:grid.410511.0) (ISNI:0000 0001 2149 7878)
4 Université Côte d’Azur, INSERM, U1065, C3M, Nice, France (GRID:grid.410511.0)
5 Division of Gastroenterology and Hepatology, Weill Cornell Medicine, Department of Medicine, New York, USA (GRID:grid.410511.0)
6 Weill Cornell Medical College, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
7 University of Lausanne, Department of Physiology, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204)
8 Université Côte d’Azur, INSERM, U1065, C3M, Nice, France (GRID:grid.9851.5); Université Côte d’Azur, CHU, INSERM, U1065, C3M, Nice, France (GRID:grid.9851.5)
9 Université Côte d’Azur, INSERM, U1065, C3M, Nice, France (GRID:grid.9851.5)